Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines

Loprevite, Maura; Favoni, Roberto E.; Cupis, Alessandra de; Pirani, Paolo; Pietra, Gabriella; Bruno, Silvia; Grossi, Francesco; Scolaro, Tindaro; Ardizzoni, Andrea

doi:10.1016/s0169-5002(00)00247-6

Cited by 23 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from studies using exponentially growing cell cultures vary from a cisplatin-induced radiosensitisation (31)(32)(33)115), to a merely additive effect (29,31,(116)(117)(118). The effect of cisplatin treatment on radiosensitivity may depend on the cell type used.…”

Section: Discussionmentioning

confidence: 99%

“…The effect of cisplatin treatment on radiosensitivity may depend on the cell type used. Loprevite et al (31) observed synergism in a squamous lung carcinoma cell line when exposed to cisplatin, whereas an adenocarcinoma of the lung was not sensitised by cisplatin (31). Even cell lines derived from a single biopsy can differ in their response to combined treatment with cisplatin and irradiation (116).…”

Section: Discussionmentioning

confidence: 99%

“…Cisplatin-based chemoradiotherapy has become standard treatment for, among others, locally advanced cervical carcinoma (30) and locally advanced non-small-cell lung cancer (NSCLC) (31). There have been numerous studies on the radiation-sensitising effect of cisplatin; however, the results vary from a clear cisplatin-induced radiosensitisation (24,25,(32)(33)(34) to a merely additive effect on cell survival (35).…”

Section: Cisplatinmentioning

confidence: 99%

See 2 more Smart Citations

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Franken

Oei

Kok

et al. 2013

International Journal of Oncology

100

View full text Add to dashboard Cite

Abstract.The linear-quadratic model (LQ model) provides a biologically plausible and experimentally established method to quantitatively describe the dose-response to irradiation in terms of clonogenic survival. In the basic LQ formula, the clonogenic surviving fraction S d ̸S 0 following a radiation dose d (Gy) is described by an inverse exponential approximation:, wherein α and β are experimentally derived parameters for the linear and quadratic terms, respectively. Radiation is often combined with other agents to achieve radiosensitisation. In this study, we reviewed radiation enhancement ratios of hyperthermia (HT), halogenated pyrimidines (HPs), various cytostatic drugs and poly(ADP-ribose) polymerase-1 (PARP1) inhibitors expressed in the parameters α and β derived from cell survival curves of various mammalian cell cultures. A significant change in the α/β ratio is of direct clinical interest for the selection of optimal fractionation schedules in radiation oncology, influencing the dose per fraction, dose fractionation and dose rate in combined treatments. The α/β ratio may increase by a mutually independent increase of α or decrease of β. The results demonstrated that the different agents increased the values of both α and β. However, depending on culture conditions, both parameters can also be separately influenced. Moreover, it appeared that radiosensitisation was more effective in radioresistant cell lines than in radiosensitive cell lines. Furthermore, radiosensitisation is also dependent on the cell cycle stage, such as the plateau or exponentially growing phase, as well as on post-treatment plating conditions. The LQ model provides a useful tool in the quantification of the effects of radiosensitising agents. These insights will help optimize fractionation schedules in multimodality treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Cisplatinmentioning

confidence: 99%

See 1 more Smart Citation

Cell survival and radiosensitisation: Modulation of the linear and quadratic parameters of the LQ model

Franken

Oei

Kok

et al. 2013

International Journal of Oncology

100

View full text Add to dashboard Cite

show abstract

“…Chemo-radiation application based on cisplatin has now become the standard treatment for, among others, locally advanced cervical carcinoma (Duenas-Gonzalez et al, 2003) and locally advanced non-small cell lung cancer (NSCLC) (Loprevite et al, 2001). …”

Section: Cisplatinmentioning

confidence: 99%

“…Results from studies using exponentially growing cell cultures vary from a cisplatininduced radiosensitization (Loprevite et al, 2001;Begg et al 1986;Nakamoto et al 1996;Huang et al 2004) to only an additive effect (Gorodetsky et al, 1998;Loprevite et al, 2001;Britten et al, 1996;Monk et al, 2002). The effect of cisplatin treatment on radiosensitivity may depend on the cell type used.…”

Section: Wwwintechopencommentioning

confidence: 99%